

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144: Filer Information

Filer CIK 0001688313  
Filer CCC XXXXXXXXX  
Is this a LIVE or TEST Filing?  LIVE  TEST

### Submission Contact Information

Name  
Phone  
E-Mail Address

## 144: Issuer Information

Name of Issuer Soleno Therapeutics, Inc.  
SEC File Number 001-36593  
Address of Issuer 203 Redwood Shores Parkway  
Suite 500  
Redwood City  
CALIFORNIA  
94065  
Phone 650-213-8444  
Name of Person for Whose Account the Securities are To Be Sold Abingworth Bioventures VII LP

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Rule 144 Affiliate

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	BTIG, LLC 350 Bush Street, 9th Floor San Francisco, CA 94104	949336	51416038	38871594	10/21/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from	Is this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------	---------------------	---------	------------	----------------------	-----------------	---------------------

Transaction	Whom Acquired	a Gift?	Acquired	Acquired	
Common Stock 10/12/2023	Acquired in multiple transactions directly from the Issuer and upon exercise of warrants.	Issuer	<input type="checkbox"/>	949336 10/12/2023	Cash consideration upon purchase or net exercise

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/07/2024	22096	1076713
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/08/2024	827801	44426341
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/09/2024	255963	13067090
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/10/2024	182489	9240275
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/11/2024	344527	18636499
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/14/2024	107810	5869500
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/15/2024	121159	6567096
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/16/2024	113899	6214079
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/17/2024	156179	8349829
Abingworth Bioventures VII LP 38 Jermyn Street London X0 SW1Y 6DN	Common Stock	10/18/2024	113450	6131450

## 144: Remarks and Signature

Remarks

Date of Notice 10/21/2024

Date of Plan Adoption or Giving of Instruction, If 09/06/2024

Relying on Rule 10b5-1

**ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Abingworth Bioventures VII LP, acting by its Manager, Abingworth LLP,  
/s/ John Heard, General Counsel

***ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)***